New research indicates that people who stop using new GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass far faster than those who end conventional lifestyle programs.
Findings released in a major medical journal shows that while obese individuals can lose substantial amounts of their total mass while on the medication, the weight returns at an average rate of nearly a kilo each month after stopping.
"Users using such treatments need to be informed of the risk of rapid weight regain when the medication concludes," stated expert Dr. Susan Jebb.
Such speed of regain means a return to starting mass in about 18 months.
Weighing Therapies
The study, which examined dozens of trials involving over 9,000 of participants, compared the results of the injectable medications with older methods.
Scientists point out that individuals who lose weight through dieting typically have a slower creep back—perhaps 100 grams monthly—after stopping.
Understanding the Quick Rebound
Experts believe the way of the drugs explains the amplified regain.
These medications mimic a body's own chemical called GLP-1, which controls feelings of fullness.
"Long-term administration of the hormone concentrations several times higher than normal could lead to the body to generate a reduced amount of its endogenous GLP-1, and could lessen sensitivity to its effects," explained Dr. Adam Collins, a nutrition expert.
"Withdrawal of this medication results in hunger is no longer kept in check, making excessive eating far more likely."
A Lifelong Condition?
Health authorities suggest the jabs for individuals with obesity-related health risks, alongside recommended diet and exercise modifications.
Professionals contend that, due to the high risk of weight regain, the therapy is often long-term.
This view is echoed by pharmaceutical companies, who note that the findings "highlight the persistent nature of obesity," similar to managing diseases like hypertension.
User Accounts
People who have come off the jabs report a powerful return of hunger.
"I experienced a trigger activating and I was suddenly ravenous," recalled one woman.
This difficulty is worsened if individuals have not adopted lasting lifestyle or habit modifications during therapy.
Widespread Use
Survey data indicate that a significant number of adults in the UK have tried these injections in the past year, with demand being substantial.
- Use is higher among females compared to men.
- The 40s and 50s demographic shows the greatest usage rates.
- Many access the drugs through private healthcare rather than public health services.
In conclusion, clinicians caution that while these medications are potent agents for shedding pounds, they are not a standalone solution and maintained weight loss hinges on ongoing behavioural management.
